Automation, Digitization, and Robotics in Cell and Gene Therapy

Source Domain: www.openpr.com

According to Precedence Research, the global automation, digitization, and robotics in cell and gene therapy manufacturing market size will grow from USD 950 million in 2025 to nearly USD 5.28 billion by 2035, expanding at a CAGR of 18.70% from 2026 to 2035. This growth is driven by the increasing adoption of cutting-edge technologies to improve the precision of complex therapies. Automation and robotics are streamlining the production of these therapies, leading to more scalable, cost-effective, and compliant manufacturing processes.

Where Data Meets Strategic Clarity 📥 View Sample Pages of the Complete Report 👉 https://www.precedenceresearch.com/sample/8329

Market Size and Forecasts

🔹 Market size in 2025: USD 950.00 Million
🔹 Market size in 2026: USD 1,127.65 Million
🔹 Market size by 2035: USD 5.28 Billion
🔹 CAGR: 18.70% (2026-2035)
🔹 Forecast period: 2026-2035
🔹 Base year: 2025

AI’s Role in Revolutionizing the Market

Artificial intelligence (AI) is playing an increasingly pivotal role in enhancing the precision and efficiency of manufacturing cell and gene therapies. AI-driven biosensors generate vast volumes of real-time data, enabling predictive insights that optimize every phase of the production process. By integrating AI into manufacturing execution systems (MES), companies can streamline workflows, enhance consistency, and reduce human error. This AI-powered innovation is unlocking the potential to scale complex therapies and ensure reproducibility across large production volumes.

Moreover, AI’s integration with digital twins and predictive modeling systems is driving the evolution of smarter manufacturing processes. By enabling real-time simulation and process optimization, AI empowers manufacturers to bring cell and gene therapies to market faster while maintaining stringent quality standards.

🔗 What’s Fueling the Next Wave of Growth? 👉

Source